Brief: Nanobiotix: Presentation Of The Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3

Nanobiotix SA

05/10/2023 06:51

Oct 5 (Reuters) - Nanobiotix SA  NANOB.PA :
    * ANNOUNCED ON WEDNESDAY: PRESENTATION OF THE FINAL EFFICACY
ANALYSIS FROM PHASE 1 COHORT EXPANSION EVALUATING NBTXR3 IN
LOCALLY ADVANCED HEAD AND NECK CANCER SHOWING MEDIAN
PROGRESSION-FREE SURVIVAL OF 16.9 MONTHS AND MEDIAN OVERALL
SURVIVAL OF 23.1 MONTHS
    * FINAL DATA FROM STUDY 102 DOSE EXPANSION SHOW THAT
RADIOTHERAPY-ACTIVATED NBTXR3 WAS FEASIBLE AND WELL TOLERATED IN
ELDERLY PATIENTS WITH A HIGH BURDEN OF COMORBIDITY (N=56)
    * CONSISTENTLY HIGH INJECTED-LESION OVERALL RESPONSE RATE OF
81.8%
AND COMPLETE RESPONSE RATE OF 63.6% IN THE EVALUABLE POPULATION
(N=44)
    * MEDIAN DURATION OF RESPONSE IN THE NBTXR3-INJECTED LESION
WAS
NOT REACHED, SUGGESTING DURABLE ANTI-TUMOR EFFICACY
    * MEDIAN PROGRESSION FREE OF 16.9 MONTHS IN THE EVALUABLE
POPULATION PER INDEPENDENT REVIEW COMMITTEE AT THE FINAL READOUT
    * RESULTS POTENTIALLY STRENGTHEN THE HYPOTHESIS AND CLARIFY
NEXT
STEPS FOR THE ONGOING GLOBAL, REGISTRATIONAL PHASE 3 STUDY
EVALUATING NBTXR3 FOR ELDERLY PATIENTS WITH LOCALLY ADVANCED
HEAD AND NECK CANCER 

Source text for Eikon:  ID:nGNXn16RT 
Further company coverage:  NANOB.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))